FDA accepts Intercept’s resubmitted NDA for obeticholic acid

FDA accepts Intercept’s resubmitted NDA for obeticholic acid

Source: 
Clinical Trials Arena
snippet: 

This article will discuss the FDA’s recent acceptance of Intercept Pharmaceuticals’s obeticholic acid (OCA) new drug application (NDA) resubmission in NASH and how OCA’s likelihood of approval compares to other drugs in late-stage development.